Going long on a high risk Biotech – due diligence to inform and update an investment thesis.
Our client, a large US based Hedge Fund, held a very significant position in a moderate-high risk NASDAQ listed biotech stock, and was looking for support in gaining greater clarity around the returns outlook of the company in question.
We provided a through clinical and commercial review of two key assets in the company’s portfolio, both through analysis of existing published data and well-placed interviews with leading experts in the field such as formed FDA review committee members. We also provided a detailed analysis vis a vis two existing competitors. Our deliverables provided our client the with greater clarity around odds and timing of approval, which was an essential component of refining their investment thesis for this important part of their share portfolio.